BioXcel Therapeutics (BTAI) EBT Margin Growth (1y) (2023 - 2026)
BioXcel Therapeutics (BTAI) EBT Margin Growth (1y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -1,585.00 |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -177.00 |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -27.00 |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | -356.00 |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 436.00 |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -629.00 |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 208.00 |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | BioXcel Therapeutics | 24.29 Mn | 24.29 Mn | 160,000.00 | 866,908.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 866,908.00 |
| Mar 31, 2026 | 132,397.00 |
| Dec 31, 2025 | -78,057.00 |
| Sep 30, 2025 | -966,036.00 |
| Jun 30, 2025 | -1.47 Mn |
| Mar 31, 2025 | -361,326.00 |
| Dec 31, 2024 | 360,430.00 |
| Sep 30, 2024 | 736,733.00 |
| Jun 30, 2024 | 1.13 Mn |
| Mar 31, 2024 | 3.68 Mn |
| Dec 31, 2023 | 6.58 Mn |
| Sep 30, 2023 | 2.67 Mn |